Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Laura M Spring, M.D.

Title
Institution
Department
Address
Phone

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Tolaney SM, Barroso-Sousa R, Keenan T, Li T, Trippa L, Vaz-Luis I, Wulf G, Spring L, Sinclair NF, Andrews C, Pittenger J, Richardson ET, Dillon D, Lin NU, Overmoyer B, Partridge AH, Van Allen E, Mittendorf EA, Winer EP, Krop IE. Effect of Eribulin With or Without Pembrolizumab on Progression-Free Survival for Patients With Hormone Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer: A Randomized Clinical Trial. JAMA Oncol. 2020 Oct 01; 6(10):1598-1605. PMID: 32880602.
    Citations:    Fields:    
  2. Smith BL, Nguyen A, Korotkin JE, Kelly BN, Specht MC, Spring LM, Moy B, Isakoff SJ, Gadd MA. A system for risk stratification and prioritization of breast cancer surgeries delayed by the COVID-19 pandemic: preparing for re-entry. Breast Cancer Res Treat. 2020 Oct; 183(3):515-524. PMID: 32712878.
    Citations:    Fields:    Translation:HumansCellsPHPublic Health
  3. McDonough AL, Lei Y, Kwak AH, Haggett DE, Jimenez RB, Johnston KT, Moy B, Spring LM, Peppercorn J. Implementation of a Brief Screening Tool to Identify Needs of Breast Cancer Survivors. Clin Breast Cancer. 2020 Jul 15. PMID: 32807644.
    Citations:    Fields:    
  4. Spring LM, Specht MC, Jimenez RB, Isakoff SJ, Wang GX, Ly A, Shin JA, Bardia A, Moy B. Case 22-2020: A 62-Year-Old Woman with Early Breast Cancer during the Covid-19 Pandemic. N Engl J Med. 2020 Jul 16; 383(3):262-272. PMID: 32610007.
    Citations: 1     Fields:    Translation:HumansCellsPHPublic Health
  5. Vidula N, Dubash T, Lawrence MS, Simoneau A, Niemierko A, Blouch E, Nagy B, Roh W, Chirn B, Reeves BA, Malvarosa G, Lennerz J, Isakoff SJ, Juric D, Micalizzi D, Wander S, Spring L, Moy B, Shannon K, Younger J, Lanman R, Toner M, Iafrate AJ, Getz G, Zou L, Ellisen LW, Maheswaran S, Haber DA, Bardia A. Identification of Somatically Acquired BRCA1/2 Mutations by cfDNA Analysis in Patients with Metastatic Breast Cancer. Clin Cancer Res. 2020 Sep 15; 26(18):4852-4862. PMID: 32571788.
    Citations:    Fields:    
  6. Bossuyt V, Spring L. Pathologic evaluation of response to neoadjuvant therapy drives treatment changes and improves long-term outcomes for breast cancer patients. Breast J. 2020 06; 26(6):1189-1198. PMID: 32468652.
    Citations:    Fields:    
  7. Hagigeorges D, Burns LJ, Isakoff SJ, Spring L, Nazarian R, Senna MM. Thermal Injury in a Patient Using a Scalp Cooling System to Prevent Chemotherapy-Induced Alopecia. JCO Oncol Pract. 2020 Aug; 16(8):522-524. PMID: 32453655.
    Citations:    
  8. Ho AY, Wright JL, Blitzblau RC, Mutter RW, Duda DG, Norton L, Bardia A, Spring L, Isakoff SJ, Chen JH, Grassberger C, Bellon JR, Beriwal S, Khan AJ, Speers C, Dunn SA, Thompson A, Santa-Maria CA, Krop IE, Mittendorf E, King TA, Gupta GP. Optimizing Radiation Therapy to Boost Systemic Immune Responses in Breast Cancer: A Critical Review for Breast Radiation Oncologists. Int J Radiat Oncol Biol Phys. 2020 Sep 01; 108(1):227-241. PMID: 32417409.
    Citations:    Fields:    
  9. Spring LM, Wander SA, Andre F, Moy B, Turner NC, Bardia A. Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future. Lancet. 2020 03 07; 395(10226):817-827. PMID: 32145796.
    Citations: 9     Fields:    Translation:Humans
  10. Spring LM, Fell G, Arfe A, Sharma C, Greenup R, Reynolds KL, Smith BL, Alexander B, Moy B, Isakoff SJ, Parmigiani G, Trippa L, Bardia A. Pathologic Complete Response after Neoadjuvant Chemotherapy and Impact on Breast Cancer Recurrence and Survival: A Comprehensive Meta-analysis. Clin Cancer Res. 2020 Jun 15; 26(12):2838-2848. PMID: 32046998.
    Citations: 4     Fields:    
  11. Drago JZ, Formisano L, Juric D, Niemierko A, Servetto A, Wander SA, Spring LM, Vidula N, Younger J, Peppercorn J, Yuen M, Malvarosa G, Sgroi D, Isakoff SJ, Moy B, Ellisen LW, Iafrate AJ, Arteaga CL, Bardia A. FGFR1 Amplification Mediates Endocrine Resistance but Retains TORC Sensitivity in Metastatic Hormone Receptor-Positive (HR+) Breast Cancer. Clin Cancer Res. 2019 11 01; 25(21):6443-6451. PMID: 31371343.
    Citations: 2     Fields:    Translation:Humans
  12. Medford AJ, Dubash TD, Juric D, Spring L, Niemierko A, Vidula N, Peppercorn J, Isakoff S, Reeves BA, LiCausi JA, Wesley B, Malvarosa G, Yuen M, Wittner BS, Lawrence MS, Iafrate AJ, Ellisen L, Moy B, Toner M, Maheswaran S, Haber DA, Bardia A. Blood-based monitoring identifies acquired and targetable driver HER2 mutations in endocrine-resistant metastatic breast cancer. NPJ Precis Oncol. 2019; 3:18. PMID: 31341951.
    Citations: 2     
  13. Goel S, Pernas S, Tan-Wasielewski Z, Barry WT, Bardia A, Rees R, Andrews C, Tahara RK, Trippa L, Mayer EL, Winer EP, Spring LM, Tolaney SM. Ribociclib Plus Trastuzumab in Advanced HER2-Positive Breast Cancer: Results of a Phase 1b/2 Trial. Clin Breast Cancer. 2019 12; 19(6):399-404. PMID: 31235441.
    Citations: 1     Fields:    Translation:HumansCTClinical Trials
  14. Wander SA, Spring LM, Bardia A. Genetics to epigenetics: targeting histone deacetylases in hormone receptor-positive metastatic breast cancer. Lancet Oncol. 2019 06; 20(6):746-748. PMID: 31036469.
    Citations: 1     Fields:    Translation:Humans
  15. Spring LM, Wander SA, Zangardi M, Bardia A. CDK 4/6 Inhibitors in Breast Cancer: Current Controversies and Future Directions. Curr Oncol Rep. 2019 02 26; 21(3):25. PMID: 30806829.
    Citations: 9     Fields:    Translation:Humans
  16. Keklikoglou I, Cianciaruso C, Güç E, Squadrito ML, Spring LM, Tazzyman S, Lambein L, Poissonnier A, Ferraro GB, Baer C, Cassará A, Guichard A, Iruela-Arispe ML, Lewis CE, Coussens LM, Bardia A, Jain RK, Pollard JW, De Palma M. Chemotherapy elicits pro-metastatic extracellular vesicles in breast cancer models. Nat Cell Biol. 2019 02; 21(2):190-202. PMID: 30598531.
    Citations: 42     Fields:    Translation:HumansAnimalsCells
  17. Zangardi ML, Spring LM, Nagayama A, Bardia A. Sacituzumab for the treatment of triple-negative breast cancer: the poster child of future therapy? Expert Opin Investig Drugs. 2019 Feb; 28(2):107-112. PMID: 30507322.
    Citations:    Fields:    Translation:Humans
  18. Spring L, Niemierko A, Haddad S, Yuen M, Comander A, Reynolds K, Shin J, Bahn A, Brachtel E, Specht M, Smith BL, Taghian A, Jimenez R, Peppercorn J, Isakoff SJ, Moy B, Bardia A. Effectiveness and tolerability of neoadjuvant pertuzumab-containing regimens for HER2-positive localized breast cancer. Breast Cancer Res Treat. 2018 Dec; 172(3):733-740. PMID: 30220055.
    Citations:    Fields:    Translation:Humans
  19. Kwan TT, Bardia A, Spring LM, Giobbie-Hurder A, Kalinich M, Dubash T, Sundaresan T, Hong X, LiCausi JA, Ho U, Silva EJ, Wittner BS, Sequist LV, Kapur R, Miyamoto DT, Toner M, Haber DA, Maheswaran S. A Digital RNA Signature of Circulating Tumor Cells Predicting Early Therapeutic Response in Localized and Metastatic Breast Cancer. Cancer Discov. 2018 10; 8(10):1286-1299. PMID: 30104333.
    Citations: 8     Fields:    Translation:HumansCells
  20. Abraham E, Post K, Spring L, Malvarosa G, Tripp E, Peppercorn JM, Bardia A, Habin K. Research Biopsies: An Integrative Review of the Experiences of Patients With Cancer. Clin J Oncol Nurs. 2018 06 01; 22(3):E71-E77. PMID: 29781452.
    Citations:    Fields:    Translation:Humans
  21. Karagounis T, Vallurupalli M, Nathan N, Nazarian R, Vedak P, Spring L, Chen ST. Stevens-Johnson syndrome-like eruption from palbociclib in a patient with metastatic breast cancer. JAAD Case Rep. 2018 Jun; 4(5):452-454. PMID: 29984280.
    Citations: 2     
  22. Spring L, Bardia A. Cycling Toward Progress: Ribociclib, a CDK 4/6 Inhibitor for Breast Cancer. Clin Cancer Res. 2018 07 01; 24(13):2981-2983. PMID: 29685881.
    Citations: 2     Fields:    Translation:Humans
  23. Condorelli R, Spring L, O'Shaughnessy J, Lacroix L, Bailleux C, Scott V, Dubois J, Nagy RJ, Lanman RB, Iafrate AJ, Andre F, Bardia A. Polyclonal RB1 mutations and acquired resistance to CDK 4/6 inhibitors in patients with metastatic breast cancer. Ann Oncol. 2018 03 01; 29(3):640-645. PMID: 29236940.
    Citations: 45     Fields:    Translation:Humans
  24. Spring L, Greenup R, Niemierko A, Schapira L, Haddad S, Jimenez R, Coopey S, Taghian A, Hughes KS, Isakoff SJ, Ellisen LW, Smith BL, Specht M, Moy B, Bardia A. Pathologic Complete Response After Neoadjuvant Chemotherapy and Long-Term Outcomes Among Young Women With Breast Cancer. J Natl Compr Canc Netw. 2017 10; 15(10):1216-1223. PMID: 28982747.
    Citations: 10     Fields:    Translation:Humans
  25. Zangardi ML, Spring LM, Blouin GC, Bardia A. Ribociclib for post-menopausal women with HR+/HER2- advanced or metastatic breast cancer. Expert Rev Clin Pharmacol. 2017 Nov; 10(11):1169-1176. PMID: 28875723.
    Citations: 4     Fields:    Translation:Humans
  26. Spring LM, Zangardi ML, Moy B, Bardia A. Clinical Management of Potential Toxicities and Drug Interactions Related to Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Practical Considerations and Recommendations. Oncologist. 2017 09; 22(9):1039-1048. PMID: 28706010.
    Citations: 10     Fields:    Translation:Humans
  27. Gazourian L, Spring L, Meserve E, Hwang D, Diaz AA, Ash SY, Ho VT, Sholl LM, Washko GR. Pulmonary Clinicopathological Correlation after Allogeneic Hematopoietic Stem Cell Transplantation: An Autopsy Series. Biol Blood Marrow Transplant. 2017 Oct; 23(10):1767-1772. PMID: 28668489.
    Citations: 2     Fields:    Translation:Humans
  28. Spring L, Bardia A. SWISH-ing steroids: new standard of care to prevent everolimus-induced oral mucositis? Lancet Oncol. 2017 05; 18(5):564-565. PMID: 28314690.
    Citations:    Fields:    Translation:Humans
  29. Spring LM, Gupta A, Reynolds KL, Gadd MA, Ellisen LW, Isakoff SJ, Moy B, Bardia A. Neoadjuvant Endocrine Therapy for Estrogen Receptor-Positive Breast Cancer: A Systematic Review and Meta-analysis. JAMA Oncol. 2016 Nov 01; 2(11):1477-1486. PMID: 27367583.
    Citations: 42     Fields:    Translation:Humans
  30. Crombie J, Spring L, Li S, Soiffer RJ, Antin JH, Alyea EP, Glotzbecker B. Readmissions after Umbilical Cord Blood Transplantation and Impact on Overall Survival. Biol Blood Marrow Transplant. 2017 01; 23(1):113-118. PMID: 27789360.
    Citations: 1     Fields:    Translation:Humans
  31. Spring LM, Marshall MR, Warner ET. Mammography decision making: Trends and predictors of provider communication in the Health Information National Trends Survey, 2011 to 2014. Cancer. 2017 02 01; 123(3):401-409. PMID: 27727457.
    Citations: 2     Fields:    Translation:HumansPHPublic Health
  32. Bychkovsky BL, Guo H, Sutton J, Spring L, Faig J, Dagogo-Jack I, Battelli C, Houlihan MJ, Yeh TC, Come SE, Lin NU. Use and Yield of Baseline Imaging and Laboratory Testing in Stage II Breast Cancer. Oncologist. 2016 12; 21(12):1495-1501. PMID: 27551013.
    Citations: 1     Fields:    Translation:Humans
  33. Spring L, Bardia A, Modi S. Targeting the cyclin D-cyclin-dependent kinase (CDK) 4/6-retinoblastoma pathway with selective CDK 4/6 inhibitors in hormone receptor-positive breast cancer: rationale, current status, and future directions. Discov Med. 2016 Jan; 21(113):65-74. PMID: 26896604.
    Citations: 17     Fields:    Translation:HumansCells
  34. Spring L, Li S, Soiffer RJ, Antin JH, Alyea EP, Glotzbecker B. Risk factors for readmission after allogeneic hematopoietic stem cell transplantation and impact on overall survival. Biol Blood Marrow Transplant. 2015 Mar; 21(3):509-16. PMID: 25482866.
    Citations: 8     Fields:    Translation:Humans
  35. Spring LM, Li S, Soiffer R, Antin JH, Alyea E, Glotzbecker B. Readmissions following umbilical cord blood stem cell transplantation. J Clin Oncol. 2014 Oct 20; 32(30_suppl):272. PMID: 28141264.
    Citations:    
  36. Spring L, Robillard D, Gehlbach L, Simas TA. Impact of pass/fail grading on medical students' well-being and academic outcomes. Med Educ. 2011 Sep; 45(9):867-77. PMID: 21848714.
    Citations: 12     Fields:    Translation:Humans
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact feedbackcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Spring's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (128)
Explore
_
Co-Authors (75)
Explore
_
Similar People (60)
Explore
_
Same Department 
Explore
_
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.